Short course of ART during primary HIV infection has immunological and virological benefits after treatment is stopped

Michael Carter
Published: 27 December 2013

A short course of antiretroviral therapy during primary HIV infection (PHI) has immunological and virological benefits after treatment is stopped, a meta-analysis published in the online journal PLoS One  shows. The benefits of treatment were greatest for people with lower baseline CD4 cell counts and higher baseline viral loads, but did not last in the long term.

“Short-course treatment during PHI was associated with better immunological and virological outcomes after treatment interruption,” write the authors. “This change is a clinically significant change, which may have a profound effect on HIV disease progression.”

Early responses to HIV infection are associated with subsequent disease progression. For instance, a recent study showed that severity of PHI is associated with longer-term outcomes. However, the benefits of short-course antiretroviral therapy during PHI are unclear. A team of investigators from China therefore performed a meta-analysis of studies examining this question that were published before September 2013.

To be included in the analysis, the studies were required to have both treatment and control arms.

The primary outcome was the effect of short-course therapy on CD4 count and viral load after the cessation of treatment. Other analyses examined the efficacy of therapy according to factors such as baseline characteristics and the duration of treatment.

A total of eight studies met the investigators’ inclusion criteria. These were published between 2004 and 2012 and had sample sizes ranging from 11 to 822 patients. The duration of short-course therapy was between 12 and 86 weeks, and participants were followed for between nine months and six years after treatment was stopped.

Pooled results showed that short-course therapy during PHI had significant immunological and virological benefits. Twelve months after stopping, early treatment increased CD4 count by 86 cells/mm3 and reduced viral load by 0.30 log10 copies/ml, compared to untreated controls.

“Theoretically, the prevention of severe loss of CD4 T cells in peripheral blood and lymphoid tissues occurring during PHI, the preservation of HIV-specific cellular and humoral immune responses, the restriction of viral diversification, and the reduced size of the HIV reservoirs exerted by treatment during PHI may be the reasons explaining these benefits,” the investigators suggest.

The investigators believe that short-course treatment during PHI had even greater benefits than those revealed in their headline finding.

They noted that, compared to untreated participants, individuals who received therapy had lower baseline CD4 counts (weighted mean difference = -77 cells/mm3) and higher viral loads (WMD = 0.22 log10 copies/ml). “After baseline correction,” write the authors, “the net changes of CD4 count and viral load derived from early treatment were much greater than those without baseline correction.”

Restricting analysis to randomised-controlled trials (RCTs) showed that participants who received short-course treatment had a CD4 count benefit of 162 cells/mm3 and a virological benefit of -0.42 log10 copies/ml, compared to participants who did not receive therapy during PHI. Benefits of early treatment were less pronounced in non-RCTs (CD4 = 72 cells/mm3; viral load = -0.25 log10 copies/ml).

But the benefits of early treatment did not last. The CD4 difference 12 to 24 months after the completion of treatment between treated and non-treated patients had fallen to 35 cells/mm3 and the viral load benefit at this time was 0.18 log10 copies/ml. These differences were not significant.

Increasing the duration of early therapy did not confer any additional benefits.

“Compared to the untreated arm, treatment during PHI not only increased CD4 count but also lowered viral load after treatment interruption,” conclude the authors. “As CD4 count and viral load are strong predictors of HIV disease progression, early treatment possibly delays HIV disease progression for at least a period of time.” They call for more research examining the risk and benefits of short-course therapy during PHI and the acceptability of this strategy to people with HIV.


Chen J et al. Immunological and virological benefits resulted from short-course treatment during primary HIV infection: a meta-analysis. PLoS One 8(12): e82461. doi: 10.1371/journal.pone.0092461, 2013.

This news report is also available in Russian.

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.